Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Kosan BioSciences -- KOSN -- Ignore unavailable to you. Want to Upgrade?

To: rkrw who wrote (68)	4/29/2002 4:41:29 PM
From: keokalani'nui	Respond to of 933

J Nat Prod 2002 Apr;65(4):570-2 Books, LinkOut Large-scale isolation and crystallization of epothilone d from myxococcusxanthus cultures. Arslanian RL, Parker CD, Wang PK, McIntire JR, Lau J, Starks C, Licari PJ. Kosan Biosciences, Inc., 3832 Bay Center Place, Hayward, California 94545. The introduction of the epothilone polyketide synthase (PKS) into Myxococcus xanthus has enabled the heterologous production of epothilone D (1) on a large scale. To isolate this valuable product from the fermentation medium, an economical, scalable, and high-yielding purification process was developed. With the crystallization of 1 from a binary solvent system that consisted of ethanol and water, the product was recovered as white crystals with a final purity of >/=97% (w/w). This is the first reported crystallization of 1.